Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study

@article{Kawashiri2008ComparisonOE,
  title={Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study},
  author={Masa-aki Kawashiri and Atushi Nohara and Hiroshi Tada and Mika Mori and Masayuki Tsuchida and Syoji Katsuda and Akihiro Inazu and Junji Kobayashi and Junji Koizumi and Hiroshi Mabuchi and Masakazu Yamagishi},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2008},
  volume={83}
}
An open, randomized, four‐phased crossover study using 4 mg of pitavastatin or 20 mg of atorvastatin was performed to compare their efficacy and safety, especially regarding plasma levels of coenzyme Q10 (CoQ10) in 19 Japanese patients with heterozygous familial hypercholesterolemia. Pitavastatin and atorvastatin caused significant and almost comparable reductions in serum levels of total cholesterol (−35.4 vs. −33.8%), low‐density lipoprotein cholesterol (−42.8 vs. −40.7%), and triglyceride… 
Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
TLDR
Bezafibrate and atorvastatin improve atherogenic dyslipidemia in considerably different ways and it is presumed that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.
Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
Aggressive low-density lipoprotein (LDL) cholesterol-lowering therapy is important for high-risk patients. However, sparse data exist on the impact of combined aggressive LDL cholesterol-lowering
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
TLDR
The safety and efficacy profile of pitavastatin is favorable for the treatment of dyslipidemia, especially in metabolic syndrome patients, and adequate control of LDL-C and TG, along with potent and incremental HDL-C elevation, with a low frequency of DDIs.
Assessing the efficacy and safety of pitavastatin compared to atorvastatin in dyslipidemic patients: a double blind randomized controlled trial
TLDR
Pitavastatin could be considered as good alternative for treatment of dyslipidemia with better HDLC levels, in addition to comparable efficacy and good tolerability of pitavASTatin, as compared to atorvastatin.
Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.
TLDR
It is revealed that long-term treatment with ATO might increase plasma levels of BNP in patients with CAD when it is accompanied by a greater reduction in plasma CoQ10, however, ATO-induced decreases in CoQ 10 might not increase oxidative stress.
Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin
TLDR
Because of its positive pleiotropic effects on coronary plaque volume and fibro-fatty composition, pitavastatin could be a valid option for the treatment of hypercholesterolemia and combined dyslipidemia.
Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus
TLDR
Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism, so it could provide an alternative treatment choice, especially in patients with glucose intolerance or diabetes mellitus.
Pitavastatin: evidence for its place in treatment of hypercholesterolemia
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C).
Pitavastatin: finding its place in therapy
  • L. Ose
  • Medicine
    Therapeutic advances in chronic disease
  • 2011
TLDR
Pitavastatin’s unique metabolic profile results in a high efficacy at low (1–4 mg) doses and minimal drug interactions with cytochrome CYP3A4 substrates, making it an excellent choice for people requiring multiple medications.
...
1
2
3
4
...

References

SHOWING 1-10 OF 46 REFERENCES
Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma
TLDR
There is a significant correlation between the CoQ10 level decrease and the decrease in total and LDL-C levels in all three treatment groups, suggesting that the Co Q10 decrease may reflect the decreaseIn the levels of its lipoprotein carriers and might not be statin-specific.
Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia
TLDR
After 3 months' atorvastatin therapy, serum levels of total cholesterol, low‐density lipoprotein cholesterol (LDL‐C) and coenzyme Q10 (0.43 ± 0.23 to 0.10 μg/mL) were all significantly reduced, suggesting that statin inhibition of coen enzyme Q10 synthesis is less strict than inhibition of cholesterol biosynthesis.
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
TLDR
Treatment with pravastatin in familial hypercholesterolemia decreases serum ubiquinone levels in proportion to the reduction in LDL cholesterol, and the amount of dolichol in serum showed a small but statistically insignificant decrease after 12 weeks of treatment.
Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH).
TLDR
When monotherapy with atorvastatin is insufficient to treat severely hypercholesterolemic patients, such as those with heterozygous FH, colestimide acts to reinforce the action of statins.
Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
TLDR
Pitavastatin is a novel, fully synthetic statin, which has a potent cholesterol-lowering action and could provide a new and potentially better therapeutic choice for lipid-modifying therapy than do the currently available statins.
Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients.
Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
TLDR
As atorvastatin reduces serum ubiquinol-10 as well as serum cholesterol levels in all patients, it is imperative that physicians are forewarned about the risks associated with ubiquinoli-10 depletion.
The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10
TLDR
The biochemistry of CoQ10, its role in cellular metabolism and the available evidence linking possible coenzyme Q10 deficiency to statin therapy are reviewed.
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells.
TLDR
Cerivastatin showed the most potent cytotoxicity in HSkMCs and strongly lowered ubiquinone levels in the rat heart, which was found to be approximately 100-fold more strongly than pitavastatin.
...
1
2
3
4
5
...